NR568 Advanced Pharmacology | Weeks 5–8 Final Exam Prep
NR568 / NR 568 ADVANCED PHARMACOLOGY
WEEKS 5–8 FINAL EXAM PREP | Latest 2026/2027 Update
150 ORIGINAL Questions & Answers with Concise Rationales
HORMONE THERAPY
1. A 52-year-old postmenopausal woman with an intact uterus presents requesting hormone therapy for
severe vasomotor symptoms. She has no contraindications to hormone therapy. Which regimen is most
appropriate?
A. Estrogen alone daily
B. Progestin alone daily
C. Combined estrogen plus progestin
D. Testosterone cream applied topically
✔ Correct Answer: C
Rationale: Women with an intact uterus who take estrogen must receive concomitant progestin to protect the
endometrium from unopposed estrogen stimulation, which markedly increases the risk of endometrial hyperplasia and
carcinoma. Progestin-only therapy does not adequately treat vasomotor symptoms. Estrogen alone is appropriate only
after hysterectomy. Testosterone is not a first-line treatment for vasomotor symptoms.
HORMONE THERAPY
2. A 58-year-old woman who had a hysterectomy 10 years ago seeks relief from persistent vaginal
dryness and dyspareunia. She prefers the lowest effective dose. Which agent is most appropriate?
A. Oral conjugated equine estrogen 0.625 mg daily
B. Low-dose vaginal estradiol cream
C. Oral medroxyprogesterone acetate
D. Transdermal testosterone patch
✔ Correct Answer: B
Rationale: Low-dose vaginal estrogen is the preferred treatment for genitourinary syndrome of menopause (GSM)
including vaginal dryness and dyspareunia; it achieves local therapeutic effects with minimal systemic absorption.
Systemic oral estrogen exposes the patient to higher risk without additional benefit for local symptoms.
Medroxyprogesterone does not treat vaginal atrophy. Testosterone is not indicated for GSM.
HORMONE THERAPY
3. A postmenopausal patient on continuous combined hormone therapy (estrogen/progestin) asks
when she should expect irregular vaginal bleeding to resolve. Which statement is most accurate?
A. Bleeding always resolves within 1 month
B. Irregular spotting may persist for 3–6 months before amenorrhea is achieved
C. Any bleeding after menopause requires immediate endometrial biopsy
D. Irregular bleeding indicates therapy failure and should be discontinued
✔ Correct Answer: B
Rationale: With continuous combined HRT, irregular breakthrough bleeding is common in the first 3–6 months as the
endometrium adjusts to continuous progestin suppression; most women achieve amenorrhea by 6 months. Bleeding
beyond 6–12 months or heavy bleeding warrants evaluation. Immediate biopsy is not required for expected early
breakthrough bleeding. Discontinuation is not indicated solely for expected early spotting.
Page 1 of 44
, NR568 Advanced Pharmacology | Weeks 5–8 Final Exam Prep
HORMONE THERAPY
4. Which of the following is the most significant absolute contraindication to systemic estrogen therapy?
A. Controlled hypertension
B. Estrogen-receptor–positive breast cancer
C. Mild type 2 diabetes mellitus
D. Elevated LDL cholesterol
✔ Correct Answer: B
Rationale: Active or history of estrogen-receptor–positive breast cancer is an absolute contraindication to systemic
estrogen therapy because exogenous estrogen can stimulate tumor growth or recurrence. Controlled hypertension, mild
diabetes, and elevated LDL are relative considerations that require risk-benefit discussion but are not absolute
contraindications.
HORMONE THERAPY
5. A 55-year-old woman on oral conjugated estrogen for hot flashes develops a new deep vein
thrombosis. Which modification best reduces future thrombotic risk while maintaining menopausal
symptom control?
A. Switch to a higher-dose oral estrogen
B. Transition to transdermal estradiol
C. Add aspirin to current oral estrogen
D. Continue oral estrogen and add warfarin
✔ Correct Answer: B
Rationale: Transdermal estradiol bypasses first-pass hepatic metabolism, thereby avoiding estrogen-induced increases
in coagulation factors and carrying a substantially lower VTE risk than oral formulations. Simply increasing oral estrogen
dose amplifies risk. Aspirin does not adequately mitigate estrogen-related VTE. Combining oral estrogen with
anticoagulation introduces bleeding risk and does not address the underlying pharmacokinetic issue.
HORMONE THERAPY
6. Ospemifene (Osphena) is prescribed for a 60-year-old woman with moderate-to-severe dyspareunia
due to vulvovaginal atrophy. She has no history of VTE. Which statement best describes its
pharmacologic classification?
A. Selective progesterone receptor modulator
B. Selective estrogen receptor modulator (SERM)
C. Gonadotropin-releasing hormone antagonist
D. Androgen receptor agonist
✔ Correct Answer: B
Rationale: Ospemifene is a SERM that acts as an estrogen agonist on vaginal tissue, improving dyspareunia from
vulvovaginal atrophy while acting as an antagonist or neutral agent in breast tissue. It is not a progesterone receptor
modulator, GnRH antagonist, or androgen agonist.
HORMONE THERAPY
7. A 54-year-old woman with a history of endometriosis is started on hormone therapy after
menopause. Which progestin formulation is preferred to minimize androgenic side effects?
A. Medroxyprogesterone acetate
B. Norethindrone acetate
C. Micronized progesterone (Prometrium)
D. Levonorgestrel
✔ Correct Answer: C
Page 2 of 44
, NR568 Advanced Pharmacology | Weeks 5–8 Final Exam Prep
Rationale: Micronized progesterone is bioidentical to endogenous progesterone and has minimal androgenic activity,
making it preferred in women sensitive to androgenic progestin side effects such as acne, hirsutism, or mood changes.
Medroxyprogesterone acetate, norethindrone, and levonorgestrel all carry some androgenic activity.
HORMONE THERAPY
8. The Women's Health Initiative (WHI) demonstrated increased risk of which adverse outcome with
combined estrogen-progestin therapy compared to placebo?
A. Hip fracture
B. Colorectal cancer
C. Breast cancer with extended use
D. Type 2 diabetes mellitus
✔ Correct Answer: C
Rationale: The WHI trial found an increase in invasive breast cancer risk with combined conjugated equine estrogen
plus medroxyprogesterone acetate after approximately 5 years of use. The same trial found reductions in hip fracture
and colorectal cancer risk. HRT is actually associated with improved insulin sensitivity and reduced T2DM incidence.
HORMONE THERAPY
9. A 50-year-old perimenopausal woman with moderate vasomotor symptoms reports mild depressive
symptoms. Which agent addresses both vasomotor symptoms and mood?
A. Raloxifene
B. Low-dose venlafaxine
C. Medroxyprogesterone acetate
D. Ospemifene
✔ Correct Answer: B
Rationale: Low-dose venlafaxine (an SNRI) has FDA-approved efficacy for reducing vasomotor symptoms and
additionally treats depression and anxiety, making it an effective non-hormonal option for women with both concerns.
Raloxifene prevents osteoporosis but does not treat hot flashes. Medroxyprogesterone and ospemifene do not address
mood symptoms.
HORMONE THERAPY
10. A patient asks about the Tissue Selective Estrogen Complex (TSEC), specifically
bazedoxifene/conjugated estrogen (Duavee). For whom is it indicated?
A. Postmenopausal women without a uterus seeking vasomotor relief
B. Postmenopausal women with an intact uterus seeking vasomotor relief without a progestin
C. Premenopausal women with heavy uterine bleeding
D. Women with estrogen-receptor–positive breast cancer
✔ Correct Answer: B
Rationale: Duavee combines conjugated estrogen with bazedoxifene, a SERM that protects the endometrium from
estrogen-driven hyperplasia, eliminating the need for a progestin. It is specifically approved for postmenopausal women
with an intact uterus. Women without a uterus do not need endometrial protection. It is not used in premenopausal
bleeding or breast cancer.
HORMONE THERAPY
11. A 67-year-old woman on long-term conjugated estrogen/medroxyprogesterone acetate wishes to
discontinue HRT. Which approach is recommended?
A. Abrupt discontinuation without tapering
Page 3 of 44
, NR568 Advanced Pharmacology | Weeks 5–8 Final Exam Prep
B. Gradual dose tapering over weeks to months
C. Switching to higher-dose progestin for 2 weeks, then stopping
D. No action needed; long-term use prevents rebound
✔ Correct Answer: B
Rationale: Gradual tapering of HRT reduces the likelihood of rebound vasomotor symptoms compared with abrupt
discontinuation. Abrupt cessation often precipitates return of hot flashes. Increasing progestin does not mitigate
estrogen withdrawal symptoms. Long-term use does not confer permanent symptom suppression once the medication
is stopped.
HORMONE THERAPY
12. Raloxifene is prescribed for a 63-year-old woman with osteoporosis. Which additional benefit
should the AGPCNP communicate to the patient?
A. Reduces hot flash severity
B. Decreases risk of invasive breast cancer
C. Improves vaginal lubrication
D. Increases uterine proliferation
✔ Correct Answer: B
Rationale: Raloxifene, a SERM, acts as an estrogen antagonist in breast tissue, reducing the risk of invasive
estrogen-receptor–positive breast cancer. It also maintains bone density. Unlike estrogen, it does not reduce hot flashes
and may actually worsen vasomotor symptoms. It antagonizes estrogen in the uterus and vagina, so it does not improve
vaginal lubrication or stimulate uterine growth.
HORMONE THERAPY
13. Which route of estrogen administration carries the lowest risk of venous thromboembolism?
A. Oral conjugated equine estrogen
B. Oral estradiol
C. Transdermal estradiol patch
D. Oral esterified estrogen
✔ Correct Answer: C
Rationale: Transdermal estradiol avoids first-pass hepatic metabolism and does not significantly increase hepatic
production of coagulation factors, conferring a substantially lower VTE risk than any oral estrogen formulation. All oral
estrogens undergo hepatic first-pass effect, increasing thrombogenic factors.
HORMONE THERAPY
14. A 62-year-old woman asks about paroxetine (Brisdelle) for hot flash management. She also takes
tamoxifen for breast cancer prevention. Which concern is most clinically relevant?
A. Paroxetine increases the risk of osteoporosis
B. Paroxetine inhibits CYP2D6 and reduces tamoxifen conversion to its active metabolite, endoxifen
C. Paroxetine causes endometrial hyperplasia
D. Paroxetine raises serum estradiol levels
✔ Correct Answer: B
Rationale: Tamoxifen requires hepatic CYP2D6 conversion to its active metabolite endoxifen for therapeutic efficacy.
Paroxetine is a potent CYP2D6 inhibitor and substantially reduces endoxifen levels, potentially compromising breast
cancer treatment. Alternative non-hormonal therapies such as venlafaxine or gabapentin, which do not significantly
inhibit CYP2D6, are preferred in women on tamoxifen.
Page 4 of 44
NR568 / NR 568 ADVANCED PHARMACOLOGY
WEEKS 5–8 FINAL EXAM PREP | Latest 2026/2027 Update
150 ORIGINAL Questions & Answers with Concise Rationales
HORMONE THERAPY
1. A 52-year-old postmenopausal woman with an intact uterus presents requesting hormone therapy for
severe vasomotor symptoms. She has no contraindications to hormone therapy. Which regimen is most
appropriate?
A. Estrogen alone daily
B. Progestin alone daily
C. Combined estrogen plus progestin
D. Testosterone cream applied topically
✔ Correct Answer: C
Rationale: Women with an intact uterus who take estrogen must receive concomitant progestin to protect the
endometrium from unopposed estrogen stimulation, which markedly increases the risk of endometrial hyperplasia and
carcinoma. Progestin-only therapy does not adequately treat vasomotor symptoms. Estrogen alone is appropriate only
after hysterectomy. Testosterone is not a first-line treatment for vasomotor symptoms.
HORMONE THERAPY
2. A 58-year-old woman who had a hysterectomy 10 years ago seeks relief from persistent vaginal
dryness and dyspareunia. She prefers the lowest effective dose. Which agent is most appropriate?
A. Oral conjugated equine estrogen 0.625 mg daily
B. Low-dose vaginal estradiol cream
C. Oral medroxyprogesterone acetate
D. Transdermal testosterone patch
✔ Correct Answer: B
Rationale: Low-dose vaginal estrogen is the preferred treatment for genitourinary syndrome of menopause (GSM)
including vaginal dryness and dyspareunia; it achieves local therapeutic effects with minimal systemic absorption.
Systemic oral estrogen exposes the patient to higher risk without additional benefit for local symptoms.
Medroxyprogesterone does not treat vaginal atrophy. Testosterone is not indicated for GSM.
HORMONE THERAPY
3. A postmenopausal patient on continuous combined hormone therapy (estrogen/progestin) asks
when she should expect irregular vaginal bleeding to resolve. Which statement is most accurate?
A. Bleeding always resolves within 1 month
B. Irregular spotting may persist for 3–6 months before amenorrhea is achieved
C. Any bleeding after menopause requires immediate endometrial biopsy
D. Irregular bleeding indicates therapy failure and should be discontinued
✔ Correct Answer: B
Rationale: With continuous combined HRT, irregular breakthrough bleeding is common in the first 3–6 months as the
endometrium adjusts to continuous progestin suppression; most women achieve amenorrhea by 6 months. Bleeding
beyond 6–12 months or heavy bleeding warrants evaluation. Immediate biopsy is not required for expected early
breakthrough bleeding. Discontinuation is not indicated solely for expected early spotting.
Page 1 of 44
, NR568 Advanced Pharmacology | Weeks 5–8 Final Exam Prep
HORMONE THERAPY
4. Which of the following is the most significant absolute contraindication to systemic estrogen therapy?
A. Controlled hypertension
B. Estrogen-receptor–positive breast cancer
C. Mild type 2 diabetes mellitus
D. Elevated LDL cholesterol
✔ Correct Answer: B
Rationale: Active or history of estrogen-receptor–positive breast cancer is an absolute contraindication to systemic
estrogen therapy because exogenous estrogen can stimulate tumor growth or recurrence. Controlled hypertension, mild
diabetes, and elevated LDL are relative considerations that require risk-benefit discussion but are not absolute
contraindications.
HORMONE THERAPY
5. A 55-year-old woman on oral conjugated estrogen for hot flashes develops a new deep vein
thrombosis. Which modification best reduces future thrombotic risk while maintaining menopausal
symptom control?
A. Switch to a higher-dose oral estrogen
B. Transition to transdermal estradiol
C. Add aspirin to current oral estrogen
D. Continue oral estrogen and add warfarin
✔ Correct Answer: B
Rationale: Transdermal estradiol bypasses first-pass hepatic metabolism, thereby avoiding estrogen-induced increases
in coagulation factors and carrying a substantially lower VTE risk than oral formulations. Simply increasing oral estrogen
dose amplifies risk. Aspirin does not adequately mitigate estrogen-related VTE. Combining oral estrogen with
anticoagulation introduces bleeding risk and does not address the underlying pharmacokinetic issue.
HORMONE THERAPY
6. Ospemifene (Osphena) is prescribed for a 60-year-old woman with moderate-to-severe dyspareunia
due to vulvovaginal atrophy. She has no history of VTE. Which statement best describes its
pharmacologic classification?
A. Selective progesterone receptor modulator
B. Selective estrogen receptor modulator (SERM)
C. Gonadotropin-releasing hormone antagonist
D. Androgen receptor agonist
✔ Correct Answer: B
Rationale: Ospemifene is a SERM that acts as an estrogen agonist on vaginal tissue, improving dyspareunia from
vulvovaginal atrophy while acting as an antagonist or neutral agent in breast tissue. It is not a progesterone receptor
modulator, GnRH antagonist, or androgen agonist.
HORMONE THERAPY
7. A 54-year-old woman with a history of endometriosis is started on hormone therapy after
menopause. Which progestin formulation is preferred to minimize androgenic side effects?
A. Medroxyprogesterone acetate
B. Norethindrone acetate
C. Micronized progesterone (Prometrium)
D. Levonorgestrel
✔ Correct Answer: C
Page 2 of 44
, NR568 Advanced Pharmacology | Weeks 5–8 Final Exam Prep
Rationale: Micronized progesterone is bioidentical to endogenous progesterone and has minimal androgenic activity,
making it preferred in women sensitive to androgenic progestin side effects such as acne, hirsutism, or mood changes.
Medroxyprogesterone acetate, norethindrone, and levonorgestrel all carry some androgenic activity.
HORMONE THERAPY
8. The Women's Health Initiative (WHI) demonstrated increased risk of which adverse outcome with
combined estrogen-progestin therapy compared to placebo?
A. Hip fracture
B. Colorectal cancer
C. Breast cancer with extended use
D. Type 2 diabetes mellitus
✔ Correct Answer: C
Rationale: The WHI trial found an increase in invasive breast cancer risk with combined conjugated equine estrogen
plus medroxyprogesterone acetate after approximately 5 years of use. The same trial found reductions in hip fracture
and colorectal cancer risk. HRT is actually associated with improved insulin sensitivity and reduced T2DM incidence.
HORMONE THERAPY
9. A 50-year-old perimenopausal woman with moderate vasomotor symptoms reports mild depressive
symptoms. Which agent addresses both vasomotor symptoms and mood?
A. Raloxifene
B. Low-dose venlafaxine
C. Medroxyprogesterone acetate
D. Ospemifene
✔ Correct Answer: B
Rationale: Low-dose venlafaxine (an SNRI) has FDA-approved efficacy for reducing vasomotor symptoms and
additionally treats depression and anxiety, making it an effective non-hormonal option for women with both concerns.
Raloxifene prevents osteoporosis but does not treat hot flashes. Medroxyprogesterone and ospemifene do not address
mood symptoms.
HORMONE THERAPY
10. A patient asks about the Tissue Selective Estrogen Complex (TSEC), specifically
bazedoxifene/conjugated estrogen (Duavee). For whom is it indicated?
A. Postmenopausal women without a uterus seeking vasomotor relief
B. Postmenopausal women with an intact uterus seeking vasomotor relief without a progestin
C. Premenopausal women with heavy uterine bleeding
D. Women with estrogen-receptor–positive breast cancer
✔ Correct Answer: B
Rationale: Duavee combines conjugated estrogen with bazedoxifene, a SERM that protects the endometrium from
estrogen-driven hyperplasia, eliminating the need for a progestin. It is specifically approved for postmenopausal women
with an intact uterus. Women without a uterus do not need endometrial protection. It is not used in premenopausal
bleeding or breast cancer.
HORMONE THERAPY
11. A 67-year-old woman on long-term conjugated estrogen/medroxyprogesterone acetate wishes to
discontinue HRT. Which approach is recommended?
A. Abrupt discontinuation without tapering
Page 3 of 44
, NR568 Advanced Pharmacology | Weeks 5–8 Final Exam Prep
B. Gradual dose tapering over weeks to months
C. Switching to higher-dose progestin for 2 weeks, then stopping
D. No action needed; long-term use prevents rebound
✔ Correct Answer: B
Rationale: Gradual tapering of HRT reduces the likelihood of rebound vasomotor symptoms compared with abrupt
discontinuation. Abrupt cessation often precipitates return of hot flashes. Increasing progestin does not mitigate
estrogen withdrawal symptoms. Long-term use does not confer permanent symptom suppression once the medication
is stopped.
HORMONE THERAPY
12. Raloxifene is prescribed for a 63-year-old woman with osteoporosis. Which additional benefit
should the AGPCNP communicate to the patient?
A. Reduces hot flash severity
B. Decreases risk of invasive breast cancer
C. Improves vaginal lubrication
D. Increases uterine proliferation
✔ Correct Answer: B
Rationale: Raloxifene, a SERM, acts as an estrogen antagonist in breast tissue, reducing the risk of invasive
estrogen-receptor–positive breast cancer. It also maintains bone density. Unlike estrogen, it does not reduce hot flashes
and may actually worsen vasomotor symptoms. It antagonizes estrogen in the uterus and vagina, so it does not improve
vaginal lubrication or stimulate uterine growth.
HORMONE THERAPY
13. Which route of estrogen administration carries the lowest risk of venous thromboembolism?
A. Oral conjugated equine estrogen
B. Oral estradiol
C. Transdermal estradiol patch
D. Oral esterified estrogen
✔ Correct Answer: C
Rationale: Transdermal estradiol avoids first-pass hepatic metabolism and does not significantly increase hepatic
production of coagulation factors, conferring a substantially lower VTE risk than any oral estrogen formulation. All oral
estrogens undergo hepatic first-pass effect, increasing thrombogenic factors.
HORMONE THERAPY
14. A 62-year-old woman asks about paroxetine (Brisdelle) for hot flash management. She also takes
tamoxifen for breast cancer prevention. Which concern is most clinically relevant?
A. Paroxetine increases the risk of osteoporosis
B. Paroxetine inhibits CYP2D6 and reduces tamoxifen conversion to its active metabolite, endoxifen
C. Paroxetine causes endometrial hyperplasia
D. Paroxetine raises serum estradiol levels
✔ Correct Answer: B
Rationale: Tamoxifen requires hepatic CYP2D6 conversion to its active metabolite endoxifen for therapeutic efficacy.
Paroxetine is a potent CYP2D6 inhibitor and substantially reduces endoxifen levels, potentially compromising breast
cancer treatment. Alternative non-hormonal therapies such as venlafaxine or gabapentin, which do not significantly
inhibit CYP2D6, are preferred in women on tamoxifen.
Page 4 of 44
